The stock has a 36-month beta value of 0.86. Opinions on the stock are mixed, with 10 analysts rating it as a “buy,” 8 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CYTK is 115.33M, and at present, short sellers hold a 12.33% of that float. On April 09, 2025, the average trading volume of CYTK was 1.80M shares.
CYTK) stock’s latest price update
Cytokinetics Inc (NASDAQ: CYTK)’s stock price has gone decline by -3.95 in comparison to its previous close of 35.99, however, the company has experienced a -7.81% decrease in its stock price over the last five trading days. investors.com reported 2025-04-02 that Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged appeared first on Investor’s Business Daily.
CYTK’s Market Performance
CYTK’s stock has fallen by -7.81% in the past week, with a monthly drop of -20.18% and a quarterly drop of -29.72%. The volatility ratio for the week is 10.36% while the volatility levels for the last 30 days are 6.43% for Cytokinetics Inc. The simple moving average for the past 20 days is -17.71% for CYTK’s stock, with a -32.18% simple moving average for the past 200 days.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with Citigroup repeating the rating for CYTK by listing it as a “Buy.” The predicted price for CYTK in the upcoming period, according to Citigroup is $86 based on the research report published on February 07, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $80. The rating they have provided for CYTK stocks is “Buy” according to the report published on January 22nd, 2025.
RBC Capital Mkts gave a rating of “Outperform” to CYTK, setting the target price at $80 in the report published on November 08th of the previous year.
CYTK Trading at -22.17% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.34% of loss for the given period.
Volatility was left at 6.43%, however, over the last 30 days, the volatility rate increased by 10.36%, as shares sank -22.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.78% lower at present.
During the last 5 trading sessions, CYTK fell by -7.81%, which changed the moving average for the period of 200-days by -33.29% in comparison to the 20-day moving average, which settled at $42.01. In addition, Cytokinetics Inc saw -26.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Malik Fady Ibraham, who sale 2,000 shares at the price of $36.18 back on Apr 08 ’25. After this action, Malik Fady Ibraham now owns 140,255 shares of Cytokinetics Inc, valued at $72,360 using the latest closing price.
FADY MALIK, the Officer of Cytokinetics Inc, proposed sale 12,000 shares at $35.99 during a trade that took place back on Apr 08 ’25, which means that FADY MALIK is holding shares at $431,880 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -29.03 for the present operating margin
- -8.9 for the gross margin
The net margin for Cytokinetics Inc stands at -31.91. The total capital return value is set at -0.44.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 1.21 points at debt to capital in total, while cash flow to debt ratio is standing at -0.5. The debt to equity ratio resting at -5.83. The interest coverage ratio of the stock is -6.2.
Currently, EBITDA for the company is -493.48 million with net debt to EBITDA at -1.4. When we switch over and look at the enterprise to sales, we see a ratio of 259.14. The receivables turnover for the company is 1.11for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.17.
Conclusion
To sum up, Cytokinetics Inc (CYTK) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
